[M24-977] A Phase 2 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination with Fluorouracil, Leucovorin, and Budigalimab as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic Gas
Clinical Trial Grant
Awarded By
AbbVie Inc.
Start Date
November 5, 2024
End Date
October 31, 2029
Awarded By
AbbVie Inc.
Start Date
November 5, 2024
End Date
October 31, 2029